Older adults, sarcopenia risk, and the trade-off nobody quantifies — setting out what I have, and where I think it stops being reliable.
Older adults: setting out the arithmetic in full, because I have had to do it twice and I would rather nobody else did.
Every step is shown. If the answer is wrong the error will be visible, which is the point of writing it out rather than posting the result.
On older adults, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Older adults has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Body weight at the extremes of the studied range affects exposure and the trials rarely reported enough to say by how much.
Post #7 is right about the mechanism and I think understates the practical bit.
Post-surgical populations, particularly after procedures affecting the gastrointestinal tract, interact with a delayed-emptying mechanism in ways that need specialist input.
Older adults would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
The most useful contribution here is usually a citation to whichever published document comes closest, with a plain statement of how far it is from the question.
Reading it back, the second half matters more than the first.
Older adults were included in the trials in smaller numbers than their share of the eventual population, so precision in that subgroup is poor.
Older adults is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
That is consistent with mine, for whatever one more account is worth.
Post #12 is right about the mechanism and I think understates the practical bit.
Genetic and ancestry-related differences in response are asked about regularly and the published evidence is thin enough that the honest answer is short.
Two sources, same conclusion, and I could not rule out that one copied the other.
Distinguishing three things in the older adults discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating.
Answering the question post #18 raises rather than the one it answers.
Nothing in this subcategory is medical advice and the questions asked here are precisely the ones that need an individual assessment.
Happy to be corrected if someone holds better data than mine.
Adding the boring version of older adults, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Narrowing post #19, because the general version has more than one answer.
Being outside the studied population does not mean a treatment is unsafe. It means the usual evidence is not available and the reasoning has to be explicit.
The literature is thinner on this than the confidence in the thread implies.
Two things can be true about older adults at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is manageable with attention.
Filing this under things that are true until someone shows me otherwise.
For anyone finding this later: the short answer on older adults is that it depends on one thing, and the rest of the thread is people identifying which thing.
Older adults is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Post #23 and I disagree about the size of the effect, not about the direction.
Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating.
I disagree with the framing of older adults above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Coming back to post #27, because the follow-up matters more than the original answer.
Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is extrapolating beyond the data.
On older adults: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.